Methods to treat opioid use disorder
AssigneeIndivior UK Limited
InventorsCeline M. Laffont, Malcolm A. Young, Norma L. Fox, Barbara R. Haight, Susan M. Learned
Life of this patent
Estimating the term…
Abstract
The disclosure provides sustained-release buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in patients to treat opioid use disorder.
Claims29
A method of treating moderate-to-severe opioid use disorder in an injection drug patient in need thereof, the method comprising subcutaneously administering a buprenorphine composition once per month for at least six months to the injection drug patient;
- wherein the buprenorphine composition comprises:
- (i) about 300 mg buprenorphine free base at 18 wt %;
- (ii) about 32 wt % of a 50:50 poly(DL-lactide-co-glycolide) copolymer having a carboxy terminal group and a weight average molecular weight of about 9,000 Daltons to about 19,000 Daltons;
- and (iii) about 50 wt % of N-methyl-2-pyrrolidone.
A method of treating opioid use disorder in an injection drug patient in need thereof, the method comprising subcutaneously administering a buprenorphine composition once per month for at least six months to the injection drug patient;
- wherein the buprenorphine composition comprises about 300 mg buprenorphine free base, a poly(lactide-co-glycolide) copolymer, and N-methyl-2-pyrrolidone.
A method of treating opioid use disorder in an injection drug patient in need thereof, the method comprising subcutaneously administering a buprenorphine composition once per month to the injection drug patient;
- wherein the buprenorphine composition comprises about 300 mg buprenorphine free base, a poly(lactide-co-glycolide) copolymer, and N-methyl-2-pyrrolidone.
Dependencies are inferred from the claim text.